Alternatively, for the STK11/KEAP1–associated gene module (Figure 4H), although we see subtle changes in increasing TMB, we see the opposite trend for PD-L1 with a 15-22% reduction in high PD-L1 cases, suggesting that more variants in this gene cluster might influence TMB levels, but may potentially be reducing the immunogenicity of the tumor, making the patient less likely to benefit from ICI treatment. This evidence concerns the gene STK11 and neoplasm.